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Homocysteine (Hcy) has been recognized for the past ﬁve decades as a risk factor for atherosclerosis. However, the role of Hcy in
the pathological changes associated with atherosclerosis as well as the pathological mechanisms triggered by Hcy accumulation is
poorly understood. Due to the reversal of the physiological direction of the reaction catalyzed by S-adenosyl-L-homocysteine
hydrolase Hcy accumulation leads to the synthesis of S-adenosyl-L-homocysteine (AdoHcy). AdoHcy is a strong product
inhibitor of S-adenosyl-L-methionine (AdoMet)-dependent methyltransferases, and to date more than 50 AdoMet-dependent
methyltransferases that methylate a broad spectrum of cellular compounds including nucleic acids, proteins and lipids have been
identiﬁed. Phospholipid methylation is the major consumer of AdoMet, both in mammals and in yeast. AdoHcy accumulation
induced either by Hcy supplementation or due to S-adenosyl-L-homocysteine hydrolase deﬁciency results in inhibition of
phospholipid methylation in yeast. Moreover, yeast cells accumulating AdoHcy also massively accumulate triacylglycerols (TAG).
Similarly, Hcy supplementation was shown to lead to increased TAG and sterol synthesis as well as to the induction of the
unfolded protein response (UPR) in mammalian cells. In this review a model of deregulation of lipid metabolism in response
to accumulation of AdoHcy in Hcy-associated pathology is proposed.
1.Introduction
The ﬁrst indication that sulfur amino acid metabolism is
linked to atherosclerosis came from observations in 1953
demonstrating that pathogenic cholesterol concentrations
and experimental atherogenesis in monkeys can be inhibited
by dietary methionine [1]. Since the early 60s elevated Hcy
levels in blood (hyperhomocysteinemia) caused by diﬀerent
deﬁciencies of sulfur amino acid metabolism were reported
to be associated with vascular disease and, in particular,
with atherosclerotic plaque formation [2, 3]. Today, Hcy is
recognized by many studies as a strong, independent and
causal risk factor for atherosclerosis [4–8], although there
is still controversy on the underlying metabolic connections
[9]. In addition to its association with vascular diseases,
Hcy is also linked to neurological disorders [10], aging [11],
and all-cause mortality [12]. Understanding the pathological
mechanisms triggered by Hcy is, therefore, essential for
understanding its role in several disease states.
Numerous mechanisms have been proposed that explain
pathological changes associated with elevated Hcy levels
(reviewed in [3]). Several of them, for example, protein
homocysteinylation and oxidative stress, are directly trig-
gered by Hcy. However, not Hcy, but rather AdoHcy, an
immediate precursor of Hcy (Figure 1), emerged as a more
sensitive indicator of cardiovascular disease during the last
decade [13, 14]. Supporting the potentially pathogenic role
of AdoHcy, studies in yeast showed that indeed AdoHcy
is more toxic than Hcy to cells that are deﬁcient in Hcy
catabolism [15].
AdoHcy is synthesized as a universal byproduct of
AdoMet-dependent methyltransferase reactions (Figure 1).
It is a strong competitive inhibitor of many AdoMet-
dependent methyltransferases [16] and, therefore, has to2 Journal of Lipids
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Figure 1: Role of AdoHcy and Hcy in AdoMet-dependent methy-
lation in yeast and mammals. The enzymes involved in yeast and
mammalian metabolism are shown in grey circles. AdoMet: S-ade-
nosyl-L-methionine; AdoHcy: S-adenosyl-L-homocysteine; Hcy:
homocysteine; Met: methionine; CTT: cystathionine; in yeast:
Sah1: S-adenosyl-L-homocysteine hydrolase; Sam1 and Sam2: S-
adenosyl-L-methionine synthetases; Met6: methionine synthase;
Str4: cystathionine β-synthase; Str1: cystathionine γ-lyase; Gsh1:
γ-glutamylcysteine synthetase; in mammals: AHCY: S-adenosyl-
L-homocysteine hydrolase; MAT: methionine adenosyltransferase;
MFMT: 5-methyltetrahydrofolate homocysteine methyltransferase;
BHMT: betaine homocysteine methyltransferase; CBS: cystathio-
nine β-synthase; CTH: cystathionine γ-lyase; GSH: glutathione
synthase.
be removed to sustain these reactions. The only eukary-
otic enzyme capable of AdoHcy catabolism, S-adenosyl-L-
homocysteine hydrolase(Sah1in yeast, AHCY in mammals),
catalyzes the reversible hydrolysis of AdoHcy to Hcy and
adenosine. The equilibrium of S-adenosyl-L-homocysteine
hydrolase-catalyzed reaction lies far in the direction of
synthesis, and both Hcy and adenosine have to be quickly
metabolized in order to drive the net hydrolysis of AdoHcy
[17]. Therefore, accumulation of hydrolytic products of the
S-adenosyl-L-homocysteine hydrolase-catalyzed reaction, in
particular Hcy, results in AdoHcy synthesis and accumula-
tion showing that AdoHcy is not only the precursor, but also
the product of Hcy metabolism in vivo [18–20].
Changes at the epigenetic level are the most exten-
sively studied consequences of methylation deﬁciency [21–
24]. However, phospholipid methylation that requires three
sequential AdoMet-dependent methylation steps to syn-
thesize one molecule of phosphatidylcholine (PC) from
phosphatidylethanolamine (PE), the predominant way for
PC synthesis in yeast, in particular, in the absence of choline
and ethanolamine in the culture medium, is the major
consumer of AdoMet. Phospholipid methylation is also
the major consumer of AdoMet in mice, since the loss of
phosphatidylethanolamine N-methyltransferase (PEMT) in
PEMT−/− knockout mice leads to a 50% decrease in plasma
Hcy levels [25]. Reexamination of methylation metabolism
in humans also revealed that phospholipid methylation, but
not creatine synthesis, as was assumed previously, accounts
for the major part of AdoMet being utilized in the human
body [26].
While PE methylation is the predominant way to synthe-
size phospholipids in yeast, phospholipid synthesis by the de
novo methylation pathway is primarily present in the liver
in mammals, where it constitutes 30% of PC production
and account for estimated 10μmol and 1,65mmol PEMT-
derived PC secreted into bile per day in mice and humans,
respectively [26, 27]. However, other mammalian tissues
and cells are also capable of phospholipid methylation
including brain, skeletal muscle, adipose tissues, ﬁbroblasts,
arterial smooth muscle cells, endothelial cells, macrophages,
and erythrocytes [28–37]. The evolutionary conservation
of phospholipid methylation suggests its essential role in
some speciﬁc functions in diﬀerent cell types. For instance,
phospholipid methylation is enhanced in hypertrophied
myocardium, correlates with the level of β-adrenergic recep-
tors [38, 39] and is stimulated by isoproterenol, a potent car-
diac stimulant [40]. In contrast, phospholipid methylation is
inhibited by quinidine, an antiarrhythmic drug that causes
repression of myocardial contractility [41]. Phospholipid
methylation was also observed in microsome preparations
from aorta [42, 43] and was suggested to aﬀect membrane
ﬂuidityandfunctionofmembranecalciumchannelsinaorta
[42, 43]a sw e l la si nh e a r t[ 40]. Moreover, phospholipid
methylation appears to be coupled to Ca2+ inﬂux and
von Willebrand factor release in endothelial cells [35]. In
accordance,itwasshownthatincreasedmethylationofphos-
pholipids is required for an inﬂux of Ca2+ and subsequent
release of histamine in mast cells [44]. Furthermore, Ca2+
inﬂux was correlated with the release of arachidonic acid in
rabbitneutrophilsandhumanﬁbroblasts,whichalsoappears
to require phospholipid methylation [32, 45]. Requirement
of phospholipid methylation for polyunsaturated fatty acid
metabolism was also observed in the brain [46]. It was
reported that developing, remyelinating, and diabetic brain
exhibits increased synthesis of PC by the de novo methylation
pathway in comparison with normal adult brain [47, 48].
Phospholipidmethylationwasshowntobelinkedtodiabetes
[49–51] and neurological disorders [52, 53] also in other
studies.
PEMT mRNA and protein levels increase substantially in
diﬀerentiating adipocytes [30]. It was shown very recently
that phospholipid methylation is required for lipid droplet
formation and stability in 3T3-L1 adipocytes, and high-fat
challenge induces PEMT expression in adipose tissue [54].
Moreover, PEMT and the CDP-choline pathway for PC syn-
thesis are both required for the secretion of very-low-density
lipoproteins [55–57]. While cells lacking the rate-limiting
enzyme of the CDP-choline pathway, CTP:phosphocholine
cytidylyltransferase, do not survive [57], deﬁciency of
phospholipid methylation in PEMT−/− mice under choline
deprivation results in development of hepatic steatosisJournal of Lipids 3
followed by steatohepatitis and hyperacute liver failure [58]
and is lethal within 5 days [59]. Moreover, deﬁciency in
phospholipid methylation, but not in the synthesis of PC
by the CDP-choline pathway, protects from diet-induced
obesityinmiceduetoincreasedenergyutilizationsuggesting
that PEMT plays a role in whole energy metabolism and
is linked to insulin signaling [60]. Finally, an isoform
of phosphatidylethanolamine N-methyltransferase, PEMT2,
appears to be involved in the control of hepatocyte cell
division, since its inactivation is associated with several types
of liver cell proliferation including tumorigenesis [61]. Vice
versa, rat hepatoma cell growth is suppressed by PEMT2
expression [62].
Sensitivity of phospholipid methylation to AdoHcy accu-
mulation [16, 18, 63]a sw e l la sn u m e r o u sc o r r e l a t i o n s
reportedforphospholipidmethylationpathwaysuggeststhat
interference with this reaction in Hcy-associated pathology
may lead to widespread defects, what indeed seems to
be the case. In particular, elevated Hcy levels were found
to trigger deregulation of lipid metabolism in yeast and
mammalian cells [18, 64]. A mechanism of deregulation of
lipid metabolism and lipid-associated cellular functions in
hyperhomocysteinemia mediated by AdoHcy accumulation
and subsequent inhibition of phospholipid methylation is
proposed in this paper.
2. Role of Homocysteinein
the Methylation Cycle
Homocysteine is a sulfur-containing amino acid, which does
not occur in proteins, but is found at the intersection
of methylation and transsulfuration metabolism (Figure 1,
reviewed in [65]). Hcy is formed during methionine
metabolism by S-adenosyl-L-homocysteine hydrolase that
catalyzes the reversible hydrolysis of AdoHcy to Hcy and
adenosine. To be kept in the methylation cycle, Hcy has
to be remethylated to methionine, which can be further
activated to AdoMet and used by over 50 AdoMet-dependent
methyltransferases that release AdoHcy as a by-product after
themethyltransferreaction.TheratioofAdoMettoAdoHcy,
that is, the ratio of the substrate versus the speciﬁc inhibitor
ofAdoMet-dependentmethyltransferases,isindicativeofthe
cellular methylation potential [66].
In addition to its remethylation to methionine, Hcy can
be subjected to transsulfuration leading to the synthesis of
cysteine, which is also a precursor of glutathione, an essen-
tial cellular defense molecule in oxidative stress response
[65]. This pathway irreversibly withdraws Hcy from the
methylation cycle. An alternative way for Hcy metabolism
is the reversal of the reaction catalyzed by S-adenosyl-L-
homocysteine hydrolase. This occurs upon accumulation of
thehydrolyticproductsofthereaction,inparticularHcy,and
leads to AdoHcy synthesis and accumulation [19, 67–69].
Thus, elevated Hcy levels via accumulation of AdoHcy lead
to the disruption of the methylation cycle and, potentially, to
methylation deﬁciency.
Deﬁciency in cystathionine β-synthase (CBS), the ﬁrst
and rate-limiting enzyme of the transsulfuration pathway
(Figure 1), is the major cause of severe hyperhomocysteine-
mia followed by genetic defects of folate and cobalamin
metabolismthatisinvolvedinHcyremethylation[65].These
pathologicalconditionsleadtotheplasmaHcylevelsofmore
than 100μmol/L [65] and are rare in comparison with mild
hyperhomocysteinemia that is caused by dietary deﬁciencies
of the vitamin cofactors required for Hcy catabolism-folic
acid, vitamins B6 and B12, and characterized by the plasma
Hcy levels of 15–25μmol/L [70]. Vitamin B6 is required
for the activity of CBS. Folic acid and vitamin B6 are
required for the activity of methionine synthase catalyzing
5-methyltetrahydrofolate-dependent remethylation of Hcy
to methionine (Figure 1). While vitamin supplementation
appeared to be a straightforward strategy to reduce/prevent
cardiovascular events, this possibility was studied in several
large trials. However, it was observed that vitamins, while
capable of lowering elevated plasma Hcy levels, do not
reduce the rates of vascular events [71]. Several potential
mechanisms that might explain this result by oﬀsetting the
positive eﬀect of Hcy-lowering therapy were subsequently
proposed. These include promotion of cell proliferation by
folic acid through its role in the synthesis of thymidine,
increase of the methylation potential leading to changes in
gene expression, and increase in the levels of asymmetric
dimethylarginine that inhibit the activity of nitric oxide
synthase [71]. An additional possibility is that, not Hcy,
but rather a related metabolite could be a trigger of some
pathological changes associated with elevated Hcy levels.
Possibly explaining the failure of Hcy-lowering vitamins
to reduce vascular events, it was recently reported that
supplementation with B-vitamins including folate does not
eﬃciently lower plasma AdoHcy levels [72], presumably due
to elevation of AdoMet-dependent methylation.
3. AdoHcy-Triggered Deregulation of
LipidMetabolisminYeast
Inyeast,thesynthesisofPCfromPEbythedenovophospho-
lipidmethylationpathwayisparticularlysensitivetoAdoHcy
accumulation [18, 63]. Both inhibition of S-adenosyl-L-
homocysteine hydrolase and Hcy supplementation results
in AdoHcy accumulation and inhibition of phospholipid
methylation in yeast [18]. However, not only phospholipid
methylation, but also a methylation-independent branch of
lipid metabolism, namely, TAG synthesis, is aﬀected by Ado-
Hcy accumulation in yeast: yeast cells deﬁcient in AdoHcy
catabolism or supplemented with Hcy massively accumulate
TAG [18]. Supporting the causal role of impaired phospho-
lipid methylation in the deregulation of TAG metabolism
in response to AdoHcy accumulation, it was found that
yeast mutants that are deﬁcient in the enzymatic activities
required for methylation of PE to PC, cho2 and opi3, also
accumulate TAG [18]. TAG is known to play an important
role in buﬀering excess fatty acids [73]. Therefore, TAG
accumulation under these conditions suggests accumulation
offattyacidsandtheirredirectionfromphospholipidtoTAG
synthesis in methylation deﬁciency in yeast.
Another observation as well supports accumulation
of fatty acids under these conditions. In addition to4 Journal of Lipids
TAG metabolism, transcriptional regulation of phospholipid
biosynthesis is also aﬀected in yeast mutants deﬁcient in
AdoHcy catabolism. Impaired phospholipid methylation in
Sah1-depleted cells unable to hydrolyze AdoHcy or in cho2
and opi3 mutants leads to upregulation of genes, which have
an inositol-sensitive upstream regulatory sequence (UASINO)
in their promoter regions, indicating accumulation of the
phospholipid precursor, phosphatidic acid, in the ER [18].
ACC1 encoding acetyl-CoA carboxylase, the ﬁrst and rate-
limiting enzyme of fatty acid biosynthesis, is also a subject
to UASINO-mediated regulation, suggesting upregulation of
the de novo fatty acid biosynthesis in response to AdoHcy
accumulation. Moreover, Sah1 depletion also aﬀects sterol
synthesis in yeast, leading to 4-fold elevated squalene levels
andsuggestingaccumulationofearlyprecursorsofergosterol
biosynthesis under these conditions (Tehlivets, Kohlwein,
unpublished). Taken together, inhibition of phospholipid
methylation induced by AdoHcy accumulation appears to
lead to upregulation of fatty acid, TAG, and sterol biosyn-
thetic pathways in yeast.
4. Phospholipid Methylation and
Homocysteine:Impact on Lipid
MetabolisminMammals
AdoHcy inhibits phosphatidylethanolamine N-methyltran-
sferase in vitro and in vivo also in mammals [28, 37, 74].
Similarly as in yeast, deﬁciency of phospholipid methylation
in PEMT−/− knockout mice leads to a rapid decrease of the
hepatic PC/PE ratio and accumulation of TAG in the liver,
in the absence of choline supplementation [75]. However,
TAG accumulation in the livers of these animals appears
to be at least in part due to decreased TAG secretion from
hepatocytes [55].
Elevated levels of Hcy are as well linked to deregulation
of lipid metabolism in mammals. CBS−/− knockout mice
exhibit severe hyperhomocysteinemia and accumulate Ado-
Hcy in all tissues tested [68, 69]. These mutant animals
show elevated TAG and nonesteriﬁed fatty acid levels in
the liver and serum and develop hepatic steatosis [76, 77].
Another genetic disorder that results in moderately elevated
Hcy levels, methylenetetrahydrofolate reductase (MTHFR)
deﬁciency, leads to fatty liver development as well as to
neuropathology and aortic lipid deposition in mouse models
[78, 79]. Dietary-induced hyperhomocysteinemia in mice
also causes fatty liver, further supporting the role of Hcy
in deregulation of lipid metabolism in mammals [64]. In
these mice as well as in the CBS−/− knockout mice lipid
accumulates in liver rather than in serum [64, 76].
Preferable accumulation of lipids in the liver and,
possibly, other tissues in hyperhomocysteinemia suggests
that other mechanisms than those associated with elevation
of circulating lipids are responsible for the development
of cardiovascular disease under these conditions. Indeed,
conventional risk factors including hypercholesterolemia
accounts only for approximately 50% of all cases of cardio-
vasculardisease,while40%ofpatiensdiagnosedwithprema-
ture coronary artery disease, peripheral vascular disease or
venous thrombosis exhibit hyperhomocysteinemia [80]. In
accordance, unlike typical lipid-rich atherosclerotic plagues,
vascular lesions associated with hyperhomocysteinemia are
lipid-poor, ﬁbrous plaques [81, 82], greatly outnumbering
fatty atherosclerotic lesions [80].
In animal models of hyperhomocysteinemia atheroscle-
rotic lesions are rare. They are found only in the MTHFR−/−
knockout mice that exhibit aortic lipid accumulation rem-
iniscent of early atherosclerotic lesions [2, 78, 83], however,
notin,forexample,CBS−/− knockoutmice.Thisdiscrepancy
might be due to disruption of two diﬀerent Hcy utilizing
pathways in these animals. While 5-methyltetrahydrofolate-
dependent Hcy remethylation occurs in all mammalian cells,
transsulfuration of Hcy occurs primarily in the liver and
kidney [65]. Thus, impairment of 5-methyltetrahydrofolate-
dependent Hcy remethylation in MTHFR−/− knockout mice
may diﬀerently aﬀect Hcy metabolism in comparison to the
deﬁciency in the ﬁrst step of Hcy transsulfuration in CBS−/−
knockout mice. The observation that dietary (methionine
or Hcy supplementation) or genetically (CBS gene deletion)
inducedhyperhomocysteinemiainapoE-deﬁcient(apoE−/−)
mice leads to development of larger and more advanced
atherosclerotic lesions clearly demonstrates a causal rela-
tionship between elevated Hcy levels and atherosclerosis
[83]. In contrast, lack of PEMT was shown to reduce
signiﬁcantly plasma VLDL and to attenuate atherosclerosis
in both PEMT−/−/Ldlr−/− mice deﬁcient in PEMT and LDL
r e c e p t o r sa sw e l la si nP E M T −/−/ApoE−/− mice [84, 85].
5. Role of the Unfolded ProteinResponse in
Hyperhomocysteinemiaand Atherosclerosis
Elevated Hcy levels induce endoplasmic reticulum (ER)
stress and activate the unfolded protein response (UPR) in
a variety of mammalian cells. These include cultured human
hepatocytes, vascular endothelial and aortic smooth muscle
c e l l sa sw e l la sl i v e rc e l l so ft h eC B S −/− knockout mice [64,
86–88]. Furthermore, elevated Hcy levels lead to activation
of the sterol regulatory element-binding proteins (SREBPs),
which function to activate genes encoding enzymes in
cholesterol,fattyacid,andTAGmetabolismanduptake,both
in cultured mammalian cell lines as well as in the livers of
the CBS−/− knockout mice [64, 86]. ER stress appears to
play a direct role in the activation of TAG and cholesterol
biosynthesis, since overexpression of the ER chaperone
GRP78/BiP was reported to inhibit Hcy-induced SREBP-1
gene expression in mammalian cell cultures [64]a sw e l la s
in mice [89] and lead to reduction of the hepatic steatosis
in leptin-deﬁcient (ob/ob)m i c e[ 89]. SREBP-1 overcomes
translation inhibition induced by UPR through an internal
ribosome entry site (IRS), similarly to GRP78 [90].
Conﬁrming the causal role of Hcy in UPR induction
and deregulation of lipid metabolism, a decrease of elevated
plasma Hcy levels is accompanied by a decrease in hepatic
lipids and ER stress response [91]. A strong correlation
between lipid metabolism, ER stress response and elevated
Hcy levels is also evident form a literature mining approach
[92]. Further demonstration of close relationship between
ER stress and Hcy metabolism came from the observationJournal of Lipids 5
that MTHFR involved in Hcy remethylation is induced in
response to ER stress [93]. Evolutionary conservation of
the relationship between Hcy and UPR is shown by the
induction of ER stress and activation of UPR in response to
Hcysupplementationinyeast[94].Finally,demonstratingits
pathophysiological role, ER stress was shown to be strongly
associatedwithacceleratedatherosclerosisinhyperhomocys-
teinemic apoE-deﬁcient mice [95], liver diseases [96]a sw e l l
as hyperglycemia-induced atherosclerosis [97].
6. Deregulation of Fatty AcidMetabolism in
Response to AdoHcy Accumulation
T h eU P R ,a sac o n s e r v e dc e l l u l a rs t r e s sr e s p o n s ep a t h w a y ,
is aimed at restoring normal ER and secretory function as
well as membrane traﬃcking upon impaired protein folding
in the ER. The de novo methylation and the CDP-choline
phospholipid biosynthetic pathways produce phospholipid
species with distinct fatty acyl chain composition in yeast:
the de novo phospholipid methylation pathway produces
more unsaturated phospholipids [98, 99]. Similarly, the
PEMT-generated PC pool in mammals is also enriched in
unsaturated fatty acids [100, 101]. Supporting the role of
PEMT in metabolism of unsaturated fatty acids PEM−/−
knockout mice were reported to accumulate more satu-
rated PC molecular species in the liver compared with
the control littermates [60] and to exhibit dramatically
reduced concentrations of polyunsaturated fatty acids in the
plasma and in hepatic PC, independently of choline status
[102]. Thus, beyond its role as a compensatory pathway for
PC biosynthesis under conditions of choline deprivation,
phospholipid methylation plays a crucial role in unsaturated
fatty acid metabolism both in yeast and in mammals. The
observation that deﬁciency of phospholipid methylation in
cho2 and opi3 yeast mutants is synthetically lethal in the
absence of a functional UPR [103] suggests an essential
requirement of UPR in response to impaired phospholipid
methylation. Thus, Hcy accumulation, which was shown
to lead to AdoHcy-mediated inhibition of phospholipid
methylation in yeast, may lead to accumulation of saturated
fatty acids in membrane phospholipids—a potential patho-
logical mechanism that might be shared by both yeast and
mammals.
Indeed, accumulation of saturated fatty acids in mem-
brane phospholipids interferes with ER structure and
integrity, induces ER stress and leads to cell death in
mammalian cell cultures [104, 105]. Accordingly, decreased
membrane phospholipid desaturation due to stearoyl-CoA
desaturase 1 knockdown induces UPR in HeLa cells [106].
Viceversa,overexpressionofstearoyl-CoAdesaturaseattenu-
atespalmitate-inducedERstressandprotectsfromlipoapop-
tosis [107–109]. Treatment with the molecular chaperone 4-
phenyl butyrate, which is capable of stabilization of protein
conformation, improvement of ER folding capacity and
facilitation of protein traﬃcking, leads to abolishment of
UPR induction in yeast subjected to lipid-induced ER stress
[105]. This ﬁnding suggests that accumulation of saturated
fatty acids in membrane phospholipids ﬁrst leads to changes
in the membrane environment followed by induction of
ER stress and accumulation of misfolded protein(s) that, in
turn, activate UPR [105]. Potential mechanisms involved in
saturated fatty acid-induced UPR include depletion of ER
Ca2+ stores leading to decreased ER chaperone activity and
protein misfolding, as well as interference with ER-to-Golgi
traﬃcking [110]. Recently, proteomic studies showed that
carboxypeptidase E, a key enzyme involved in processing
[111] and sorting of insulin [112], is involved in induction
of ER stress in β-cells in response to palmitate treatment
[113]. Degradation of carboxypeptidase E in palmitate-
induced ER stress is mediated by palmitate metabolism and
Ca2+ ﬂux [113]. Alternatively, changes of the ER membrane
environment may directly activate ER sensors IRE1, ATF6,
and PERK or modulate the binding of the ER sensors to the
ER chaperone GRP78 causing its dissociation and activation
of UPR pathways.
Supporting the hypothesis that Hcy interferes with phos-
pholipid acyl chain composition it was observed in humans
that elevated plasma AdoHcy levels are negatively correlated
with both PC content and the level of polyunsaturated fatty
acids in PC, but not in PE, in red blood cells in Alzheimer’s
patients [114]. Elevated plasma Hcy levels were also shown
to be associated with a decrease in polyunsaturated (docosa-
hexaenoic) fatty acids in the plasma of healthy humans [115]
and in the plasma and erythrocytes of cystic ﬁbrosis patients;
these individuals exhibit increased Hcy and AdoHcy levels as
well as altered PE and PC metabolism [116].
Taken together, deﬁciency of phospholipid methyla-
tion caused by AdoHcy accumulation in Hcy-associated
pathology appears to lead to an increase in saturated PC
molecular species in ER membranes followed by ER stress,
protein misfolding, induction of UPR, and activation of lipid
metabolism (Figure 2). Upregulation of lipid biosynthesis,
which apparently should serve to compensate for suboptimal
composition of membrane lipids, leads, however, to accu-
mulation of fatty acids, TAG and sterols in the absence of
functional phospholipid methylation. In addition to a role
in formation of a speciﬁc pool of PC molecular species,
phospholipid methylation is crucial for maintenance of a
distinctPC/PEratioimportantforcellintegritywhendietary
choline-supply is blunted. Decrease of the PC/PE ratio was
reported to result in increased cell permeability of hepato-
cytes from PEMT−/− mice fed choline deﬁcient diet leading
to liver damage [75]. Similarly, decrease of PC or increase in
PE was shown to lead to cell damage and/or death in several
other mammalian cell types [117–119]. Finally, observation
of diﬀerent outcomes in hyperhomocysteinemic apoE−/−
mice and both in PEMT−/−/Ldlr−/− and PEMT−/−/ApoE−/−
mice suggests mechanisms besides inhibition of phospho-
lipid methylation, for example, AdoHcy-dependent modu-
lation of gene expression that may also contribute to the
development of Hcy-dependent atherosclerosis.
7. Concluding Remarks
The metabolism of homocysteine, consequences of its accu-
mulation as well as associated AdoHcy-triggered inhibition
of AdoMet-dependent methylation are complex. In this
paper a novel mechanism of Hcy-triggered deregulation6 Journal of Lipids
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Figure 2: A model of activation of UPR and upregulation of
fatty acid, TAG, and sterol biosynthesis in response to inhi-
bition of phospholipid methylation in hyperhomocysteinemia.
Elevated Hcy levels via AdoHcy accumulation and inhibition
of phospholipid methylation lead to accumulation of saturated
PC molecular species in ER membranes followed by ER stress,
UPR activation, and upregulation of fatty acid, TAG, and sterol
biosynthesis. The enzymes involved in yeast and mammalian
metabolism are shown in grey circles (see Figure 1). PE: phos-
phatidylethanolamine; PC: phosphatidylcholine; PEMT: phos-
phatidylethanolamine N-methyltransferase in mammals; Cho2 and
Opi3: phosphatidylethanolamine N-methyltransferases in yeast.
of lipid metabolism and UPR induction that is mediated
through an AdoHcy-dependent inhibition of phospholipid
methylation and based on experimental evidence derived
from both yeast and mammalian systems is proposed. The
observations made in yeast and mammals are summarized
in Table 1.
S-adenosyl-L-homocysteinehydrolaseisrecognizedsince
many years as a target for antiviral drug design [120].
Inhibitors that block AdoHcy hydrolysis are eﬃcient against
many types of viruses including Ebola and show other eﬀects
of pharmacological importance [120–122]. However, they
are associated with high cytotoxicity due to interference
Table 1: Experimental evidence on deregulation of lipid
metabolism and UPR induction under elevated homocysteine
levels in yeast and mammals∗.
Experimental evidence Yeast Mammals
AdoHcy is formed in vivo in
response to elevated Hcy levels ++
AdoHcy is more toxic than Hcy
to cells deﬁcient in Hcy
catabolism
+
AdoHcy represents a better
marker of cardiovascular risk
than Hcy
+
Phospholipid methylation is
quantitatively the major
consumer of AdoMet
++
Phospholipid methylation is
inhibited in response to Hcy
supplementation
+
Phospholipid methylation is
inhibited by AdoHcy ++
TAG is accumulating in response
to Hcy supplementation ++
TAG is accumulating in response
to deﬁciency in AdoHcy
hydrolysis
+
TAG is accumulating in response
to deﬁciency in phospholipid
methylation
++
UPR is inducted in response to
Hcy supplementation ++
The de novo phospholipid
methylation pathway produces
phospholipids enriched in
unsaturated fatty acids
++
ER stress is inducted by
accumulation of saturated fatty
acids in membrane
phospholipids
++
Hcy/AdoHcy levels are inversely
correlated to the levels of
unsaturated fatty acids
+
∗The absence of a plus sign in some columns implies lack of data or
nonapplicability.
with central metabolic pathways [121, 122]. While using
these inhibitors to study the eﬀects of AdoHcy accumu-
lation appears to be straightforward, ability of some of
nucleoside inhibitors of S-adenosyl-L-homocysteine hydro-
lase to undergo metabolic phosphorylation to nucleotides
may account for a part of their biological activities [121,
122]. Inhibitors that would be able to block selectively
homocysteine and adenosine conversion to AdoHcy are
not available. However, based on current understanding of
regulation of homocysteine and methionine metabolism (i)
selective blockage of AdoHcy synthesis from homocysteine
and adenosine that will relieve not only inhibition ofJournal of Lipids 7
phospholipid methylation but also many other AdoMet-
dependent methyltransferase reactions, combined with (ii)
vitamin B6 supplementation in order to accelerate homo-
cystein catabolism by transsulfuration pathway, may serve as
a way to reduce AdoHcy in hyperhomocysteinemia without
elevation of AdoMet.
Many questions in the model presented in this paper
are still unanswered. Is AdoHcy-mediated accumulation
of saturated fatty acids in membrane lipids indeed the
way by which elevated Hcy levels induce ER stress? What
role do speciﬁc lipid precursors have in regulation of
lipid metabolism in UPR? What is the impact of AdoHcy
accumulation on other methylation reactions unrelated to
lipid metabolism? What is the role of deﬁcient phospholipid
methylation in homocysteine-associated pathology beyond
deregulation of fatty acid, TAG, sterol metabolism, and
UPR induction? Elucidation of the molecular mechanisms
triggered by elevated Hcy levels will undoubtfully improve
our understanding of its pathological role in numerous
diseases.
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